drugset / Trial / NCT06536465
The Clostridioides Difficile Trial of REC-3964
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK) and efficacy of REC-3964 (doses of either 250 mg or 500 mg PO every 12 hours) for the reduction of Clostridioides difficile infection (CDI).
Timeline
- Start
- 2024-10-14
- Primary completion
- 2025-05-06
- Completion
- 2025-05-06
Outcome
Outcome not reported
Stopped (Business): “Study was terminated due to sponsor decision. This decision was not related to safety concerns.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | REC-3964 | Unknown | 250 mg | Oral |
| Subject | REC-3964 | Unknown | 500 mg | Oral |